This study is in progress, not accepting new patients
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
a study on Colorectal Cancer
Colorectal Carcinoma Programmed Cell Death-1 (PD1, PD-1) Programmed Death-Ligand 1 (PDL1, PD-L1) MSI-H MSI Carcinoma Colorectal Neoplasms Pembrolizumab
Lead Scientist at UCSF
- Chloe Atreya
Dr. Chloe E. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer, at the UCSF Helen Diller Comprehensive Cancer Center. Her research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the goal of improving patient outcomes and quality of life by personalizing treatment.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Merck Sharp & Dohme Corp.
- Phase 2
- Study Type
- Last Updated